Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine to fight breast cancer is currently in the pipeline. It targets the Bcl-2 protein, which appears to contribute…  
  • “If you had been diagnosed with chronic myeloid leukemia (CML) in 1999, chances were that you would not be alive today. Just 3 out of 10 patients survived for…  
  • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • An experimental drug has been found to extend the lives of kidney patients by about 3.5 months–from 7 to just under 11. It has also been shown to delay…